159783-41-2

Basic information

• Product Name: Benzoic acid, 3-(1-methylethoxy)-4-nitro-, methyl ester
• CAS NO: 159783-41-2
• Molecular Formula: C11H13NO5
• Molecular Weight: 239.228
• Mol File: 159783-41-2.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-(1-methylethoxy)-4-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-(1-methylethoxy)-4-nitro-, methyl ester(159783-41-2)
• EPA Substance Registry System: Benzoic acid, 3-(1-methylethoxy)-4-nitro-, methyl ester(159783-41-2)

Safety Data

• Hazardous Substances Data: 159783-41-2(Hazardous Substances Data)

Upstream product

• 713-52-0 methyl 3-hydroxy-4-nitrobenzoate 
• 75-26-3 isopropyl bromide 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 75-30-9 2-iodo-propane 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 1373319-34-6 4-(5-(5-amino-6-isopropoxypicolinamido)-6-isopropoxypicolinamido)-3-isopropoxybenzoic acid 
• 1373319-35-7 4-(5-(4-amino-3-isopropoxybenzamido)-6-isopropoxypicolinamido)-3-isopropoxybenzoic acid 
• 1373319-36-8 5-(5-(4-amino-3-isopropoxybenzamido)-6-isopropoxypicolinamido)-6-isopropoxypicolinic acid 
• 1006030-83-6 methyl 3-isopropoxy-4-(3-isopropoxy-4-nitro-benzoylamino)-benzoate 
• 1318208-92-2 isopropyl 3-isopropoxy-4-(3-isopropoxy-4-nitrobenzamido)benzoate 
• 681465-85-0 4-amino-3-isopropoxybenzoic acid methyl ester 
• 379261-85-5 3-(isopropyloxy)-4-nitrobenzoic acid 

Relevant articles and documents

Synthesis and biological evaluation of cystobactamid 507: A bacterial topoisomerase inhibitor from Cystobacter sp.

Abstract The first total synthesis of cystobactamid 507, a member of a class of new natural products with strong inhibitory activity towards bacterial topoisomerases, is reported. Synthetic key challenges are the central tetrasubstitued arene and the low chemical reactivity of anilines and ortho-phenolic and isopropoxy-substituted benzoic acids. Biological evaluations demonstrate that cystobactamid 507 inhibits several Gram-positive pathogens but at significantly lower concentrations than described for the larger members of this natural product family.

An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors

ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but none of the described synthetic compounds has so far reached the market. To optimise the activities and physicochemical properties of our previously reported N-phenylpyrrolamide inhibitors, we have synthesized an improved, chemically variegated selection of compounds and evaluated them against DNA gyrase and topoisomerase IV enzymes, and against selected Gram-positive and Gram-negative bacteria. The most potent compound displayed IC50 values of 6.9 nM against Escherichia coli DNA gyrase and 960 nM against Staphylococcus aureus topoisomerase IV. Several compounds displayed minimum inhibitory concentrations (MICs) against Gram-positive strains in the 1–50 μM range, one of which inhibited the growth of Enterococcus faecalis, Enterococcus faecium, S. aureus and Streptococcus pyogenes with MIC values of 1.56 μM, 1.56 μM, 0.78 μM and 0.72 μM, respectively. This compound has been investigated further on methicillin-resistant S. aureus (MRSA) and on ciprofloxacin non-susceptible and extremely drug resistant strain of S. aureus (MRSA VISA). It exhibited the MIC value of 2.5 μM on both strains, and MIC value of 32 μM against MRSA in the presence of inactivated human blood serum. Further studies are needed to confirm its mode of action.

A structure—activity relationship study of bis-benzamides as inhibitors of androgen receptor—coactivator interaction

The interaction between androgen receptor (AR) and coactivator proteins plays a critical role in AR-mediated prostate cancer (PCa) cell growth, thus its inhibition is emerging as a promising strategy for PCa treatment. To develop potent inhibitors of the